Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
8 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Adaptive Biotechnologies President and COO Julie Rubinstein sold 35,643 common shares Oct. 14-16, 2026. She exercised stock options for 35,643 common shares at $12.14 per share during the same period. Her direct common stock holdings remained at 377,802 shares; remaining stock options totaled 237,205. Disclaimer: This
Adaptive Biotechnologies President and COO Julie Rubinstein sold 35,643 shares on Oct. 9, Oct. 12, Oct. 13. Sales prices: $26.41, $25.35, $26.07, $25.5. * Holdings fell to 377,802 shares following the transactions. * Trades followed option exercises of 11,881 shares at $12.14 on each date. Disclaimer: This news brief w
Adaptive Biotechnologies Chief People Officer Francis Lo sold 26,792 shares on Oct. 1, 2026, with proceeds of $770,481. The shares were exercised from options and the executive's direct holdings rose to 220,867.
Company sold 4,087,500 common shares at $0.08 each in a non-brokered placement. Two directors bought 750,000 shares for $60,000.
Susan Bobulsky, Adaptive Biotechnologies’ Chief Commercial Officer, sold 1,195 common shares on Sep. 15 at $27 per share.
() -- Harlan S Robins, Chief Scientific Officer, on July 02, 2026, sold 386,240 shares in Adaptive Biotechnologies (ADPT) for $8,501,149. Following the Form 4 filing with the SEC, Robins has control over a total of 1,019,658 common shares of the company, with 1,019,658 shares held directly. SEC Filing: Copyright © 2026
() -- Francis Lo, Chief People Officer, on July 01, 2026, sold 95,842 shares in Adaptive Biotechnologies (ADPT) for $2,157,683. Following the Form 4 filing with the SEC, Lo has control over a total of 233,213 common shares of the company, with 230,713 shares held directly and 2,500 controlled indirectly. SEC Filing: Co
Harvest Investment Services sells 356,000 Adaptive Biotechnologies shares worth $5.7 million, reducing its stake in the company. This sale may impact ADPT's stock price.